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Essentials
• The response of thromboelastometry (ROTEM) param-
eters to therapy is unknown.
• We prospectively recruited hemorrhaging trauma patients
in six level-1 trauma centres in Europe.
• Blood products and pro-coagulants prevent further
derangement of ROTEM results.
• ROTEM algorithms can be used to treat and monitor
trauma induced coagulopathy.
Summary. Background: Rotational thromboelastometry
(ROTEM) can detect trauma-induced coagulopathy (TIC)
and is used in transfusion algorithms. The response of
ROTEM to transfusion therapy is unknown. Objectives: To
determine the response of ROTEM profiles to therapy in
bleeding trauma patients. Patients/Methods: A prospec-
tive multicenter study in bleeding trauma patients (receiv-
ing ≥ 4 red blood cell [RBC] units) was performed. Blood
was drawn in the emergency department, after administration
of 4, 8 and 12 RBC units and 24 h post-injury. The response
of ROTEM to plasma, platelets (PLTs), tranexamic acid
(TXA) and fibrinogen products was evaluated in the whole
cohort as well as in the subgroup of patients with ROTEM
values indicative of TIC. Results: Three hundred and nine
bleeding and shocked patients were included. A mean dose
of 3.8 g of fibrinogen increased FIBTEM CA5 by 5.2 mm
(IQR: 4.1–6.3 mm). TXA administration decreased lysis by
5.4% (4.3–6.5%). PLT transfusion prevented further
derangement of parameters of clot formation. The effect of
PLTs on EXTEM ca5 values was more pronounced in
patients with a ROTEM value indicative of TIC than in the
whole cohort. Plasma transfusion decreased EXTEM clot-
ting time by 3.1 s ( 10 s to 3.9 s) in the whole cohort and
by 10.6 s ( 45 s to 24 s) in the subgroup of patients with
a ROTEM value indicative of TIC. Conclusion: The effects
of therapy on ROTEM values were small, but prevented
further derangement of test results. In patients with
ROTEM values indicative of TIC, the efficacy of PLTs and
plasma in correcting deranged ROTEM parameters is pos-
sibly more robust.
Keywords: hemorrhage; ROTEM; transfusion; trauma;
viscoelastic hemostatic assay.
Introduction
Trauma-induced coagulopathy (TIC) develops in up to
25% of severely injured trauma patients, aggravates
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massive hemorrhage, and is associated with increased
mortality [1,2]. Current resuscitation practices often
include an empirical balanced resuscitation approach with
administration of red blood cells (RBCs), plasma and pla-
telets (PLTs) in a 1 : 1 : 1 ratio [3–5]. Although this non-
specific strategy reduces the development of dilutional
coagulopathy, it may not correct different pre-existing
forms of coagulopathy that are present in individual
patients [6,7]. Also, this empirical approach fails to correct
TIC in recipients of large volumes of blood [8,9]. Imple-
mentation of the empirical 1 : 1 : 1 strategy, often as part
of massive transfusion protocols, has increased the amount
of blood products transfused [10]. As transfusion is also
associated with adverse outcomes, including infections [11]
and organ failure [12–15], the outcome of traumatic bleed-
ing is probably optimal with a targeted, precision-medicine
approach to the management of TIC, leading to improved
outcomes while avoiding unnecessary transfusion.
This precision approach requires monitoring of the
effects of therapy. Clotting tests, such as prothrombin time,
activated partial thromboplastin time, and PLT count, have
limited usefulness in guiding resuscitation strategy [16–18].
Viscoelastic hemostatic assays (VHAs), such as thrombelas-
tography (TEG) and rotational thromboelastometry
(ROTEM), are rapid tests that can identify TIC in trauma
patients [19–21]. A trial in which trauma patients were ran-
domized to either TEG or conventional tests to guide labo-
ratory-based transfusion therapy showed a survival benefit
for the TEG-guided arm, while the amount of blood prod-
ucts needed was decreased [22]. These results are promising,
although the effects need to be validated in larger multicen-
ter trials. Also, the response of VHA parameters to therapy
given during bleeding is not known. Therefore, existing
algorithms only provide threshold levels that trigger ther-
apy [22–25]. In order to identify effective therapy for TIC,
algorithms based on VHA parameters need to be refined.
The aim of this study was to determine the response of
ROTEM parameters to therapy in bleeding trauma patients.
Methods
As part of a prospective multicenter observational study,
termed the Activation of Coagulation and Inflammation
in Trauma study (United Kingdom Clinical Research
Network Study Portfolio, ID: 5637), this study was per-
formed in six European level 1 trauma centers, i.e. Lon-
don, Oslo, Copenhagen, Oxford, Cologne, and
Amsterdam, which are members of the International
Trauma Research Network (INTRN). All adult trauma
patients (aged ≥ 18 years) who required full trauma team
activation, who received at least 4 units of RBCs within
24 h, and who were still alive after 24 h, were recruited
between January 2008 and April 2015. Patients who
received > 2 L of intravenous fluids prior to arrival at the
hospital, who arrived in the emergency department (ED)
> 2 h after injury, who were transferred from other
hospitals and who had burns covering > 5% of the total
body surface area were not eligible. Patients were retro-
spectively excluded if they declined to give informed con-
sent, were taking anticoagulant medications other than
aspirin (< 650 mg daily), had moderate or severe liver dis-
ease (Child’s classification B or C3), had a known bleed-
ing diathesis, had no ROTEM measurements available, or
died within 24 h post-injury.
Written informed consent was obtained from each
patient. When the patient was unconscious, written
informed consent was obtained from a legal representa-
tive. This study was conducted according to the State-
ment of the Declaration of Helsinki, and was performed
after approval by the local ethics committees.
The following data were collected prospectively and
placed in a centralized database: data on patient demo-
graphics, time of injury, trauma mechanism, vital signs
and laboratory test results up to 24 h post-injury, Injury
Severity Score (ISS), Abbreviated Injury Scale score, 24-h
and 28-day mortality, total fluids (crystalloids, colloids,
and hypertonic saline), amount of RBC units, plasma and
PLT units, and antifibrinolytic (tranexamic acid [TXA])
and procoagulant agents (fibrinogen concentrates and cry-
oprecipitate).
Blood sampling and ROTEM assays
Blood was drawn and collected in citrated tubes immedi-
ately on arrival at the ED and at 24 h post-injury. Addi-
tionally, during resuscitation with blood component
therapy, blood samples were drawn after administration
of 4, 8 and 12 RBC units. The dose of plasma and PLTs
given in the intervals between blood draws was also
prospectively collected. Two ROTEM assays (EXTEM
and FIBTEM) were performed by trained personnel after
blood samples were taken. These assays were chosen on
the basis of our previous results obtained when we were
determining threshold values for TIC [26]. Within each
assay, six ROTEM parameters were analyzed: the clotting
time (CT), the clot amplitude after 5 min (CA5), the clot
amplitude after 10 min, the angle of tangent at 20-mm
amplitude (a angle), the maximum clot firmness, and the
lysis index of the clot after 30 min (LY30).
In this same patient cohort, we recently determined
ROTEM thresholds with a high detection rate for TIC, as
measured on ED arrival [26]. FIBTEM CA5 had the high-
est diagnostic performance in detecting a low fibrinogen
level (< 2.0 g dL1), with a cut-off value of < 10 mm.
EXTEM-FIBTEM CA5 had the highest diagnostic perfor-
mance in detecting a low PLT count (< 100 9 109 L1),
with a threshold of 30 mm. EXTEM LY30 below 85% was
associated with sudden increases in RBC requirements and
mortality. EXTEM ca5 had the highest diagnostic perfor-
mance in detecting coagulopathy, as defined by an Interna-
tional Normalized Ratio (INR) of > 1.2, with a CA5
threshold of 40 mm. The response of ROTEM parameters
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to treatment was investigated in all bleeding patients, as
well as in those patients with a ROTEM profile corre-
sponding to TIC upon ED arrival. The number of PLT
units was corrected for the number of pooled donors, as
this differs between centers.
The effect of plasma and PLT therapy on ROTEM
parameters was analyzed by relating the therapy given
within a time interval to changes in ROTEM results in
the following measurement. These intervals are the base-
line to 4 RBC units time point, the 4 RBC units to 8
RBC units time point, and the 8 RBC units to 12 RBC
units time point. This approach was chosen because VHA
parameters change rapidly in response to blood products.
To describe the effects of TXA and fibrinogen products
on ROTEM VHA profiles, the change between baseline
and 24-h measurements was used. Intervals in which a
ROTEM value was missing, and the change for ROTEM
values could therefore not be calculated, were left out.
This resulted in a variable amount of intervals that could
be evaluated. There was no loss of data regarding the 28
day mortality. Other outcome data were not gathered, as
the denominator of measurements comprises intervals and
not patients.
Transfusion strategy
In all trauma centers, issuing of blood products, antifibri-
nolytic agents and procoagulant agents by the blood bank
was performed through locally implemented massive trans-
fusion protocols (MTPs). In most centers, the MTP was
activated for patients with a systolic blood pressure of
< 90 mmHg and with an inadequate response to fluid
administration, and for whom there was a suspicion of
ongoing bleeding. Centers empirically applied blood prod-
ucts in a fixed ratio. Administration of TXA, followed by
continuous infusion for a period of 8 h, was used as a prin-
cipal component of the MTP in all centers. Cryoprecipitate
was used in London, Oxford, and Copenhagen, and fib-
rinogen concentrates were used in Oslo, Cologne, and Ams-
terdam. The trigger for use of these concentrated fibrinogen
products differed between centers, from a fibrinogen level
of ≤ 1.0 g L1 to a fibrinogen level of ≤ 2.0 g L1. Centers
had a restrictive approach to the use of fluids, but there
was no shared protocol on fluid management. Differences
in protocols have been described previously [27].
Statistics
Sample size was not prespecified in this exploratory study,
as ROTEM responses to therapy have not been described
before. Patient characteristics and ROTEM values are
given in the tables, and expressed as mean and standard
deviation (SD) if normally distributed; non-normally dis-
tributed data are expressed as median and interquartile
ranges. Categorical data are presented as frequencies and
percentages. To test for differences in patient characteristics
and ROTEM profiles, Student’s t-test and Mann–Whitney
U-tests were used. Categorical variables were compared by
use of the chi-square test. For multiple comparisons, a one-
way ANOVA was used. A P-value of < 0.05 was considered
to be statistically significant.
Results
In total, 309 patients for whom ROTEM profiles were
available were transfused with ≥ 4 RBC units (their char-
acteristics are shown in Table 1). Most patients had sus-
tained a blunt trauma, were in shock, and were
coagulopathic, as reflected by a prolonged mean INR and
decreased levels of fibrinogen. The mean baseline
ROTEM variables were mostly within the reference val-
ues as provided by the manufacturer (Table 2). All mea-
surements together yielded 426 time intervals in which the
effect of transfusion strategy on the ROTEM profiles
could be determined, although the amount of intervals
available for analysis varied per treatment and per test.
ROTEM response to treatment with fibrinogen
Of the 309 patients, 119 (39%) received fibrinogen prod-
ucts, containing a mean of 3.8 g (SD 1.2 g) of fibrinogen.
Patients given fibrinogen products were more severely
injured, as reflected by a higher ISS, and more acidotic
than those not receiving fibrinogen (Table S1). Also,
baseline fibrinogen levels were lower in patients receiving
fibrinogen. Despite this, in the whole group of patients
receiving fibrinogen, administration of fibrinogen prod-
ucts resulted in a greater increase in FIBTEM parameters
than in patients not receiving fibrinogen (Table 3). In
patients with a ROTEM profile known to correspond
with a low fibrinogen level (FIBTEM CA5 < 10 mm)
[26], the response to therapy was the same as in the whole
cohort receiving fibrinogen.
Table 1 Baseline characteristics and outcome of patients receiving
≥ 4 red blood cell units
N = 309 (SD)
Age (years) 44.8 (1.1)
Male gender (%) 73
Trauma mechanism, blunt (%) 83
ISS 29.1 (0.7)
SBP (mmHg) 106.2 (1.9)
Heart rate (beats min–1) 110.2 (1.7)
Lactate (mmol L1) 5.1 (4.4)
GCS 10.8 (0.3)
Hb (g dL1) 12.5 (0.1)
Platelet count (9 109 L1) 214.2 (4.1)
INR 1.22 (0.1)
Fibrinogen (g L1) 1.9 (0.1)
Base excess (mEq L–1)  7.5 (0.4)
28-day mortality (%) 22.9
GCS, Glasgow Coma Score; Hb, hemoglobin; INR, International Nor-
malized Ratio; ISS, Injury Severity Score; SBP, systolic blood pressure.
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ROTEM response to treatment with platelets
Of the 309 patients, 212 (69%) received PLTs. Patients
given PLTs had lower baseline platelet counts than those
not receiving PLTs, although the PLT count was normal in
most patients (Table S2). In all patients, EXTEM parame-
ters of clot formation worsened during the course of bleed-
ing and treatment (Table 4). In the whole group of patients
receiving PLTs, EXTEM values were higher during man-
agement than in those not receiving PLTs, although the
difference did not reach statistical significance. In patients
with a ROTEM profile known to correspond to low PLT
levels [26], the decrease in EXTEM ca5 was significantly
less than in those not receiving therapy.
ROTEM response to treatment with plasma
Of the 309 patients, 280 (91%) received plasma. The
patients receiving plasma were more shocked, as reflected
by a higher heart rate and lower base excess (Table S3). In
the whole group of patients receiving plasma, plasma trans-
fusion significantly reduced EXTEM CT, with a mean of
3.1 s, as compared with patients not receiving plasma
(Table 5), in whom EXTEM CT was prolonged during
bleeding and management. In those patients with an
EXTEM CT known to correspond to coagulopathy,
ROTEM responses to therapy were more pronounced, with
an EXTEM CT reduction of 10.6 s, although statistical sig-
nificance was not reached, owing to a wide confidence inter-
val. It is of note that the amount of intervals was small.
ROTEM response to treatment with TXA
Use of TXA was not registered in 19 patients. Of the
remaining 290 patients, 112 (39%) received TXA. Patients
given TXA were more severely injured, as reflected by a
higher ISS, and were more shocked and more acidotic
than those not receiving TXA (Table S4). In the whole
group of patients receiving TXA, administration of TXA
resulted in greater improvements in lysis and FIBTEM
parameters than in patients not receiving TXA (Table 6).
In those patients with a LY30 suggestive of hyperfibrinol-
ysis [26], the response to therapy was the same as in the
whole cohort receiving TXA.
Discussion
The results indicate that, during management of patients with
traumatic bleeding, almost all of the ROTEM profiles show
further deterioration. This study suggests that the effect of
treatment with transfusion products and procoagulant ther-
apy with the aim of improving deranged ROTEM parameters
can be monitored during traumatic hemorrhage. Fibrinogen,
plasma, PLTs and TXA improve ROTEM parameters of clot
formation and firmness, and decrease clot lysis. Although the
effects can be described as modest, it must be noted that these
improvements were detected during ongoing resuscitation of
patients who were actively bleeding. In the subgroup of
patients with ROTEM threshold values that were previously
identified to correspond to coagulopathy (i.e. low fibrinogen
levels, thrombocytopenia, increased fibrinolysis, and/or an
INR of > 1.2), the efficacy of plasma and PLTs in correcting
ROTEM parameters was possibly more robust than in the
whole bleeding population receiving treatment.
We previously showed that, in the same cohort of
patients, administration of fibrinogen did not result in
Table 2 Baseline rotational thromboelastometry variables of patients
receiving ≥ 4 red blood cell units
N = 309
EXTEM CT (s) 70.3 (2.0)
EXTEM CA5 (mm) 39.7 (0.6)
EXTEM CA10 (mm) 49.6 (0.7)
EXTEM MCF (mm) 58.5 (0.6)
EXTEM a angle (°) 67.9 (0.6)
EXTEM LY30 (%) 96.9 (1.0)
EXTEM CFT (s) 136.4 (10.9)
FIBTEM CA5 (mm) 10.0 (0.3)
FIBTEM CA10 (mm) 10.9 (0.3)
FIBTEM MCF (mm) 12.7 (0.4)
FIBTEM a angle (°) 61.7 (0.5)
FIBTEM LY30 (%) 94.9 (1.0)
CA5, clot amplitude after 5 min; CA10, clot amplitude after 10 min;
CFT, clot formation time; CT, clotting time; LY30, lysis index of
the clot after 30 min; MCF, maximum clot firmness. Data are mean
and standard error of the mean.
Table 3 Rotational thromboelastometry (ROTEM) response to fibrinogen
All patients
receiving fibrinogen
Patients with
FIBTEM CA5 < 10
receiving fibrinogen
Patients not
receiving fibrinogen
N = 119 intervals N = 82 intervals N = 190 intervals
FIBTEM CA5 (mm) 5.0 (3.9–6.1)* 5.1 (3.8–6.4)* 2.4 (1.5–3.3)
FIBTEM CA10 (mm) 5.5 (4.2–6.8)* 5.5 (4.1–7.0)* 2.8 (1.8–3.7)
FIBTEM MCF (mm) 5.8 (4.1–7.4)* 5.8 (3.8–7.9)* 2.1 (0.8–3.6)
FIBTEM a angle (°) 8.4 (5.3–11.6)* 8.4 (5.4–11.4)* 3.2 (1.0–5.5)
CA5, clot amplitude after 5 min; CA10, clot amplitude after 10 min; Data are median and interquartile range (IQR); MCF, maximum clot
firmness. *P < 0.05 versus not receiving fibrinogen. ROTEM response was determined in the interval between baseline and t = 24 h.
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correction of low fibrinogen levels in patients who are
actively bleeding [28]. Here, we show that a mean dose of
fibrinogen of 3.8 g improves EXTEM ca5 levels by 5 mm.
Therefore, this ROTEM marker may guide fibrinogen dos-
ing in patients with traumatic bleeding. Notably, it was
shown previously that low fibrinogen levels are associated
with adverse outcomes in patients with traumatic hemor-
rhage [29–31]. Unfortunately, we cannot provide further
analysis of the effect of fibrinogen dose on correction of
ROTEM parameters, because the exact timing of fibrino-
gen administration was not noted.
For monitoring of the effect of TXA, there are cur-
rently no conventional clotting tests available at the bed-
side. In this study, 1 g of TXA improved all early
markers of clot formation, and decreased markers of
lysis. It was shown previously that TXA administration is
associated with a good outcome [28]. Taken together, the
results indicate that monitoring of the effect of procoagu-
lant therapy on TIC is possible during the management
of bleeding trauma patients.
Plasma transfusion reduced EXTEM CT, whereas, in
patients not receiving plasma, EXTEM CT was further
prolonged during bleeding. As EXTEM CT is a marker
of TIC that occurs very early during ROTEM testing, the
results suggest that EXTEM CT may guide the specific
need for an increased dose of plasma. Note that, as low
fibrinogen levels affect the whole coagulation process, and
fibrinogen will also reduce EXTEM CT, one may first
consider correcting a fibrinogen deficiency with fibrinogen
concentrates prior to considering additional plasma.
In severe injury, a drop in the PLT count occurs late
[32]. Therefore, the PLT count as such may not be a
Table 4 Rotational thromboelastometry (ROTEM) response to platelets
All patients
receiving platelets
Patients with
EXTEM ca5 – FIBTEM
CA5 < 30 receiving platelets
Patients not receiving
platelets
N = 137 intervals N = 25 intervals N = 103 intervals
EXTEM ca5 (mm)  1.55 ( 4.48 to 1.37) 0.74 ( 4.77 to 6.25)*  4.39 ( 6.06 to  2.72)
EXTEM CA10 (mm)  1.14 ( 4.24 to 1.95) 0.53 ( 5.6 to 6.66)  4.13 ( 5.96 to  2.3)
EXTEM MCF (mm)  0.11 ( 2.77 to 2.55) 1.45 ( 3.92 to 6.81)  2.67 ( 4.58 to  0.75)
EXTEM a angle (°) 0.43 ( 2.96 to 3.82) 1.18 ( 5.8 to 8.16)  3.34 ( 5.07 to  1.62)
CA5, clot amplitude after 5 min; CA10, clot amplitude after 10 min; Data are median and interquartile range (IQR); MCF, maximum clot
firmness. *P < 0.05 versus not receiving platelets. ROTEM response was determined in intervals during resuscitation therapy.
Table 5 Rotational thromboelastometry (ROTEM) response to plasma
All patients receiving
plasma
Patients with
EXTEM CT > 80 and
CA5 > 40 receiving plasma
Patients not
receiving plasma
N = 117 intervals N = 17 intervals N = 42 intervals
EXTEM CT (s)  3.1 ( 10.0 to 3.9)*  10.6 ( 45.7 to 24.2) 10.8 ( 0.8 to 22.3)
EXTEM MCF (mm)  1.7 ( 3.3 to  0.1)  5.2 ( 12.1 to 1.7)  4.1 ( 7.9 to  0.4)
EXTEM CFT (s) 19.5 (4.7–34.3) 30.31 (1.2–59.4) 37.4 (5.4–69.4)
CT, clotting time; CFT, clot formation time; Data are median and interquartile range (IQR); MCF, maximum clot firmness. *P < 0.05 versus
not receiving plasma. ROTEM response was determined in intervals during resuscitation therapy.
Table 6 Rotational thromboelastometry (ROTEM) response to tranexamic acid (TXA)
All patients
receiving TXA
Patients with
EXTEM LY30 < 85%
receiving TXA
Patients not
receiving TXA
N = 76 intervals N = 34 intervals N = 170 intervals
EXTEM LY30 (%) 5.4 (4.3–6.5)* 5.4 (4.1–6.7)* 3.0 (2.1–3.9)
FIBTEM CA5 (mm) 6.0 (4.8–7.3)* 6.1 (4.6–7.5)* 3.6 (2.6–4.5)
FIBTEM CA10 (mm) 6.1 (4.4–7.9)* 6.1 (3.6–8.6)* 3.2 (1.7–4.6)
FIBTEM MCF (mm) 8.1 (5.3–10.9)* 8.1 (5.0–11.2)* 3.3 (0.8–5.8)
FIBTEM a angle (°) 5.4 (4.4–6.5)* 5.4 (4.1–6.7)* 3.0 (2.1–3.9)
FIBTEM LY30 (%) 6.0 (4.8–7.3)* 6.0 (4.5–7.5)* 3.6 (2.6–4.5)
CA5, clot amplitude after 5 min; CA10, clot amplitude after 10 min; LY30, lysis index of the clot after 30 min; Data are median and interquartile
range (IQR); MCF, maximum clot firmness. *P < 0.05 versus not receiving TXA. ROTEM response was determined in the interval between
baseline and t = 24 h.
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useful transfusion trigger. In this study, in which most
patients had normal PLT counts, the derangement of
EXTEM parameters of clot formation was less pro-
nounced in patients receiving PLT transfusion, which
may suggest that EXTEM parameters are more useful
then PLT counts in monitoring effects of therapy.
Previously, in the same cohort of patients, threshold
ROTEM values corresponding to TIC and adverse out-
comes were identified [26]. With these values, algorithms
for guidance of the management of patients with TIC
were constructed. The aim of this study was to provide
follow-up data. Here, we show that, in bleeding patients,
transfusion of plasma and PLTs in those patients with
ROTEM levels that would trigger therapy according to
threshold values corresponding to TIC [26] resulted in
more improvement of ROTEM values than in the whole
group of bleeding patients. However, the effect of plasma
did not reach statistical significance, probably because of
a loss of data points. Whether use of the algorithm to
guide therapy results in better outcomes while reducing
unnecessary transfusion is currently under investigation in
a randomized controlled trial [33].
Limitations of this study should be acknowledged.
Studies were performed in patients with ongoing bleeding,
in whom the rate of bleeding most likely affected
ROTEM results, but this is impossible to account for.
Another issue is that blood products were administered
together, making it impossible to attribute an effect on
ROTEM values to a specific therapy. However, these
issues reflects real-life clinical practice. Another important
limitation is that we were not able to report on ROTEM
changes in response to different doses of fibrinogen and
TXA. This remains an area that needs to be explored.
Also, exsanguinating patients were excluded, in order to
provide for follow-up samples. Therefore, the results may
not apply to the most severely bleeding patients. Also, as
most patients in this study had sustained blunt injuries, it
remains to be determined whether the response to therapy
is the same in patients with penetrating injury. Finally,
transfusion protocols differ between centers, which is a
limitation of this observational study.
Conclusion
VHAs such as ROTEM can be used for monitoring of
treatment for TIC during ongoing traumatic hemorrhage.
In patients with ROTEM threshold values known to cor-
respond to coagulopathy, the efficacy of plasma and
PLTs was possibly clearer than in the whole bleeding
population, suggesting that ROTEM-based algorithms
can be used to treat and monitor TIC.
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